Suven Life Sciences Ltd - 530239 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the half-year ended September 30, 2019 Suven Life Sciences Ltd - 530239 - Clarification
With reference to Movement in Volume, Suven Life Sciences Ltd has submitted to BSE a copy of Clarification is enclosed. Suven Life Sciences Ltd - 530239 - Increase In Volume
Please find attached Reply on Increase in volume
Buy Suven Life Sciences with target Rs 387: AnandRathi
Considering the lower-than-anticipated RD cost and operating expenses, we raise our FY20e and FY21e EBITDA respectively 16.7% and 22.8%. Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer''s Disease (AD)
Suven Life Sciences share price jumps 4%
The company says the phase 2 data for its SUVN 502, a drug for Alzheimer's disease, will be out in a week. Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement regarding to Financial Results of the Company Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached Investor Presentation Suven Life Sciences Ltd - 530239 - Un-Audited Standalone And Consolidated Financial Results Under Ind AS For The Quarter And Half-Year Ended 30Th September, 2019
Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter and half-year ended 30th September, 2019 SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find enclosed herewith an invitation for conducting the conference call for investors on Friday, November 15, 2019 at 11:30 A.M. IST to discuss the Un-audited Financial Results for the Q2 & H1 Financial Year 2020, to be declared on 14th November, 2019.